<qa>  What is the safety profile of the combination biotherapy regimen?This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b HDI and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of locallyregionally advancedrecurrent melanoma. Also, the objectives of this trial include the evaluation of prognostic and predictive biomarkers, radiologic preoperative response rate, pathologic response rate, progression free survival and overall survival. Up to 30 evaluable patients will be accrued. 